Characterization and Cytotoxicity of Pseudomonas Mediated Rhamnolipids Against Breast Cancer MDA-MB-231 Cell Line

Neelam Mishra; Kavita Rana; Siva Deepthi Seelam; Rakesh Kumar; Vijyendra Pandey; Bharathi P Salimath; Dayanand Agsar

doi:10.3389/fbioe.2021.761266

Characterization and Cytotoxicity of Pseudomonas Mediated Rhamnolipids Against Breast Cancer MDA-MB-231 Cell Line

Front Bioeng Biotechnol. 2021 Nov 30:9:761266. doi: 10.3389/fbioe.2021.761266. eCollection 2021.

Authors

Neelam Mishra¹, Kavita Rana², Siva Deepthi Seelam¹, Rakesh Kumar³, Vijyendra Pandey⁴, Bharathi P Salimath^{5

6}, Dayanand Agsar¹

Affiliations

¹ Department of Microbiology, Gulbarga University, Gulbarga, India.
² Department of Toxicology, Chaudhary Charan Singh University, Meerut, India.
³ Department of Life Science, School of Life Sciences, Central University of Karnataka, Kadaganchi, India.
⁴ Department of Psychology, School of Social and Behavioural Sciences, Central University of Karnataka, Kadaganchi, India.
⁵ Department of Biotechnology, University of Mysore, Mysore, India.
⁶ Sanorva Biotech Pvt. Ltd., Mysuru, India.

Abstract

A biosurfactant producing bacterium was identified as Pseudomonas aeruginosa DNM50 based on molecular characterization (NCBI accession no. MK351591). Structural characterization using MALDI-TOF revealed the presence of 12 different congeners of rhamnolipid such as Rha-C8-C8:1, Rha-C10-C8:1, Rha-C10-C10, Rha-C10-C12:1, Rha-C16:1, Rha-C16, Rha-C17:1, Rha-Rha-C10:1-C10:1, Rha-Rha-C10-C12, Rha-Rha-C10-C8, Rha-Rha-C10-C8:1, and Rha-Rha-C8-C8. The radical scavenging activity of rhamnolipid (DNM50RL) was determined by 2, 3-diphenyl-1-picrylhydrazyl (DPPH) assay which showed an IC₅₀ value of 101.8 μg/ ml. The cytotoxic activity was investigated against MDA-MB-231 breast cancer cell line by MTT (4,5-dimethylthiazol-2-yl-2,5-diphenyl tetrazolium bromide) assay which showed a very low IC50 of 0.05 μg/ ml at 72 h of treatment. Further, its activity was confirmed by resazurin and trypan blue assay with IC₅₀ values of 0.01 μg/ml and 0.64 μg/ ml at 72 h of treatment, respectively. Thus, the DNM50RL would play a vital role in the treatment of breast cancer targeting inhibition of p38MAPK.

Keywords: MDA-MB-231 cell lines; MTT; TNBC; cytotoxic; p38MAPK; resazurin; rhamnolipid; trypan blue.